Structure Therapeutics Inc (GPCR) Stock Price, Quote & News

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in pre...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 457 1978

Website: structuretx.com

Address:

601 Gateway Boulevard, Suite 900, South San Francisco, United States

BIOTECH_GURU Mar. 28 at 8:03 PM

$GPCR thus guy is not too sharp. If you do 100% opposite of what he says you will be golden.

0 · Reply

deltaivan Mar. 28 at 7:58 PM

$GPCR DVLT has one of the cleaner balance sheet setups you will find in this part of the market. The company ended 2025 with about $116M in working capital and no long-term debt, which matters because most names at this size are constantly leaning on dilution just to stay alive. That financial cushion gives management room to execute instead of survive. In a market full of small caps fighting cash burn, having capital strength and no debt overhang is a real competitive advantage

0 · Reply

NYChichas Mar. 28 at 7:17 PM

$GPCR Why thiss down.? Same faith as VKTX.?

0 · Reply

MetalFistSlip3 Mar. 27 at 7:28 PM

$GPCR down 15% oof

2 · Reply

biolover Mar. 26 at 12:20 PM

$VKTX FMR And fee bio funds loaded up to their ears on the $WVE “ differentiated “ wt loss mechanism 😂 They did same thing on $GPCR

0 · Reply

BioRich Mar. 25 at 3:26 PM

$ALT They don't always hit, but when they are an $ALT competitor, it just hits better. @Designed2Gain, is it time to pop the Anejo and celebrate yet? Congrats $TERN family on the $6B+ Buyout. $GPCR next, followed by a deal for $GUTS. Exciting times for the sector and for @BioRich followers. Follow/Subscribe for more suggestions and perspective Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! Follow/Subscribe for more

0 · Reply

biolover Mar. 25 at 1:45 PM

$GPCR $VKTX these TV interviews and CNBC support means nothing when data so obvious. Look at the volume first hour.

0 · Reply

Theflash88 Mar. 25 at 7:12 AM

$TERN $VKTX or $GPCR next.

0 · Reply

BioRich Mar. 25 at 3:23 AM

$ALT @@Turribull, you realize ANYONE that has been realistic and followed for any period of time expected $TERN to get a deal. $GPCR as well, and $GUTS too (leaning partneship initially). Lee, your desparate $ALT pumps and fabricated comparisons are falling on deaf ears. Game over.

0 · Reply

Capitulation_0 Mar. 25 at 3:22 AM

$GPCR Another wide eyed CEO that thinks he can turn this into MRK... IMCR CEO welcomes you to the club.

0 · Reply

Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster

Mar 17, 2026, 7:45 AM EDT - 12 days ago

Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target

Mar 16, 2026, 12:32 PM EDT - 13 days ago

Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript

Mar 16, 2026, 10:46 AM EDT - 13 days ago

Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?

Mar 16, 2026, 9:27 AM EDT - 13 days ago

Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16%

Mar 16, 2026, 7:00 AM EDT - 13 days ago

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Feb 26, 2026, 4:02 PM EST - 4 weeks ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Feb 18, 2026, 4:51 PM EST - 5 weeks ago

Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?

Feb 3, 2026, 1:27 PM EST - 7 weeks ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN LLY NVO PFE VKTX

Jan 21, 2026, 10:05 AM EST - 2 months ago

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Jan 15, 2026, 6:21 PM EST - 2 months ago

Structure CEO Ray Stevens talks its obesity drug portfolio

Dec 11, 2025, 4:01 PM EST - 3 months ago

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Dec 9, 2025, 11:15 PM EST - 3 months ago

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Dec 9, 2025, 8:30 AM EST - 3 months ago

Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)

Dec 8, 2025, 7:27 PM EST - 3 months ago

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Dec 8, 2025, 5:18 PM EST - 3 months ago

Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Dec 8, 2025, 4:01 PM EST - 3 months ago

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Dec 8, 2025, 12:46 PM EST - 3 months ago

Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

Dec 8, 2025, 11:20 AM EST - 3 months ago

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Dec 8, 2025, 8:14 AM EST - 3 months ago

Structure's experimental pill shows 11% weight loss in study, shares up

Dec 8, 2025, 8:00 AM EST - 3 months ago

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Dec 7, 2025, 6:20 PM EST - 4 months ago

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Nov 10, 2025, 6:21 PM EST - 4 months ago

Final Trade: UBER, CRWV, GPCR, DIS

CRWV UBER DIS

Nov 6, 2025, 4:01 PM EST - 5 months ago

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 5, 2025, 6:21 PM EST - 5 months ago

Fast Money: DAL, ROKU, AAPL, GPCR

AAPL ROKU DAL

Sep 10, 2025, 1:54 PM EDT - 7 months ago

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 6, 2025, 4:01 PM EDT - 8 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Jun 23, 2025, 6:10 PM EDT - 9 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Jun 20, 2025, 7:30 PM EDT - 10 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Apr 14, 2025, 10:49 AM EDT - 1 year ago

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

VKTX

Mar 27, 2025, 7:40 AM EDT - 1 year ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Mar 24, 2025, 6:26 PM EDT - 1 year ago

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:23 PM EDT - 1 year ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Mar 20, 2025, 9:28 AM EDT - 1 year ago

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Jan 30, 2025, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 6, 2025, 2:53 PM EST - 1 year ago

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

VKTX

Dec 17, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 5, 2024, 6:17 PM EST - 1 year ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Nov 15, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 13, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Oct 22, 2024, 2:07 PM EDT - 1 year ago

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Aug 23, 2024, 3:17 PM EDT - 1 year ago

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Jun 11, 2024, 6:37 PM EDT - 1 year ago

Structure Therapeutics CEO on GLP drugs

Jun 7, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 5, 2024, 7:53 PM EDT - 1 year ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 3, 2024, 6:27 PM EDT - 1 year ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

BIOTECH_GURU Mar. 28 at 8:03 PM

$GPCR thus guy is not too sharp. If you do 100% opposite of what he says you will be golden.

0 · Reply

deltaivan Mar. 28 at 7:58 PM

0 · Reply

NYChichas Mar. 28 at 7:17 PM

$GPCR Why thiss down.? Same faith as VKTX.?

0 · Reply

MetalFistSlip3 Mar. 27 at 7:28 PM

$GPCR down 15% oof

2 · Reply

biolover Mar. 26 at 12:20 PM

$VKTX FMR And fee bio funds loaded up to their ears on the $WVE “ differentiated “ wt loss mechanism 😂 They did same thing on $GPCR

0 · Reply

BioRich Mar. 25 at 3:26 PM

0 · Reply

biolover Mar. 25 at 1:45 PM

$GPCR $VKTX these TV interviews and CNBC support means nothing when data so obvious. Look at the volume first hour.

0 · Reply

Theflash88 Mar. 25 at 7:12 AM

$TERN $VKTX or $GPCR next.

0 · Reply

BioRich Mar. 25 at 3:23 AM

0 · Reply

Capitulation_0 Mar. 25 at 3:22 AM

$GPCR Another wide eyed CEO that thinks he can turn this into MRK... IMCR CEO welcomes you to the club.

0 · Reply

twincam Mar. 25 at 2:28 AM

$TERN thesis playing out — ~$6B $MRK buyout chatter validating the setup. Positioning: • Long Jan’27 $70C • Avg: $7.95 → Now: $12.25 • +54% unrealized • Spot: ~$55 (above breakeven trajectory) Not calling victory — but finally on the right side of the tape. Time to start recouping prior losses while managing risk into confirmation. 👀 Rotation watch: $VKTX $GPCR $PYPL — where’s the next asymmetric setup?

0 · Reply

SuperGreenToday Mar. 25 at 12:54 AM

$GPCR Share Price: $47.11 Contract Selected: Oct 16, 2026 $50 Calls Buy Zone: $6.54 – $8.09 Target Zone: $12.31 – $15.05 Potential Upside: 78% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

biolover Mar. 24 at 4:10 PM

$GPCR $VKTX can’t r/o clueless CEO moving on GPCR. But come on. Escalation that last > 9 months. Wt loss of only 6.4% at 20 Wks with 2.5 starting dose and 23% vomit while not reaching 1/3 of final dose. And increased liver enzymes. ? How dump ? Let us see how much FMR guy make on this investment. Invest on dinner rumors. ?

0 · Reply

Theflash88 Mar. 23 at 4:13 PM

$GPCR BO

1 · Reply

Teillbou Mar. 23 at 3:22 PM

$GPCR I heard last part of CNBC call. I did not feel that a partnership or BO was on the table at all but let's see. But maybe I missed something before CEO clearly said he was not looking for a BO but only partnership. Still bullish

0 · Reply

Mjstockwit Mar. 23 at 3:04 PM

$GPCR if Faber on CNBC says he’s aware of outside interest in the company - as an M&A reporter - shouldn’t he talk about who or is he just pumping up his own book?

0 · Reply

TrustButVerifi Mar. 23 at 3:03 PM

$VKTX $GPCR over 30% D/C first 28 weeks!

1 · Reply

TrustButVerifi Mar. 23 at 3:00 PM

$VKTX $GPCR Structure CEO spewing Best in Class (my Ass)!

0 · Reply

Teillbou Mar. 23 at 2:53 PM

$GPCR some people know...

0 · Reply

biolover Mar. 21 at 2:53 PM

$VKTX TZP half life 5 days. Vk2835 8.5 days. It can make a difference. Particularly with orals that can accumulate. Could be more difficult to make TZP oral. We don’t know if $LLY attempted. If orfoglipron shows liver toxicity ( my estimate 1/300 pts ) …again If. Lilly will find itself behind here. $GPCR could show ALT > x5-10 at 1-100-200 .. will see. I could be wrong here. AZN orfor like molecule had one case of liver toxicity in phase 1. Look at exposure. I think VK2735 could be slightly exaggerated on this modeling as phase 2 had more females. But if it beats by 1% at 12 wks. It can make a difference long term. This is what $NVO needs.

0 · Reply

chuckieclam Mar. 21 at 2:30 AM

$GPCR 68 to 49 in a month

0 · Reply

blocktrade Mar. 20 at 2:33 PM

$GPCR will finish green today.

0 · Reply

Market Cap	3.25B
Revenue (ttm)	0.00
Net Income (ttm)	-141.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,299,900
Avg Vol	986,776
Day's Range	N/A - N/A
Shares Out	70.84M
Stochastic %K	9%
Beta	-1.80
Analysts	Strong Sell
Price Target	$109.00